Gj. Marek et al., Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex, J PHARM EXP, 292(1), 2000, pp. 76-87
Citations number
47
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
In prefrontal cortex, 5-hydroxytryptamine(2A) (5-HT2A) receptors have been
linked to the action of hallucinogens and atypical antidepressant/antipsych
otic drugs. Previously, we have shown in cortical layer V pyramidal cells t
hat a nonselective metabotropic glutamate (mGlu) receptor agonist suppresse
s the induction of excitatory postsynaptic potentials/currents (EPSPs/EPSCs
) via activation of 5-HT2A receptors. In this study, we tested the ability
of the selective mGlu2/3 agonist (1S, 2S, 5R, 6S)-2-aminobicyclo[3.1.0] hex
ane-2,6-dicarboxylate monohydrate (LY354740) and the selective mGlu2/3 anta
gonist 2S-2-amino-2-( 1S,2S-2-carboxycycloprop-1-yl)-3(xanthy-9-yl) propano
ic acid (LY341495) to modulate serotonin(5-HT)-induced EPSPs and electrical
ly evoked EPSPs by using intracellular recording from layer V pyramidal cel
ls in medial prefrontal cortex. The mGlu2/3 antagonist LY341495 increased t
he frequency and amplitude of 5-HT-induced EPSCs, suggesting a role for mGl
u2/3 receptors in mediating the action of endogenous glutamate on autorecep
tors. Conversely, the mGlu2/3 agonist LY354740 was highly effective and pot
ent (EC50 = 89 nM) in suppressing glutamate release induced by 5-HT2A recep
tor activation in the medial prefrontal cortex, probably via a presynaptic
mechanism. The mGlu2/3 antagonist LY341495 potently blocked the suppressant
effect of LY354740 on 5-HT-induced EPSCs as well as electrically evoked ea
rly EPSPs. Autoradiography with the radioligands [H-3] LY354740 and [I-125]
(+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane shows a striking overla
p of the laminar distribution of mGlu2/3 and 5-HT2A receptors in the medial
prefrontal cortex that is not apparent in other cortical regions. These fi
ndings suggest a close coupling between mGlu2/3 and 5-HT2A receptors in the
prefrontal cortex that may be relevant for novel therapeutic approaches in
the treatment of neuropsychiatric syndromes such as depression and schizop
hrenia.